Episode 55: Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia

Join endocrine experts Vin Tangpricha, MD, PhD, FACE, Editor-in-Chief of Endocrine Practice (EP) and Professor of Medicine at Emory University School of Medicine, and Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, Director of Inpatient Diabetes at Long Island Jewish Medical Center, Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Northwell Health, and Chair Elect for the AACE 2025 Annual Meeting, as they discuss Dr. Schulman-Rosenbaum’s EP article, “Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia.” Tune in as they explore the complexities of managing inpatient hyperglycemia, the risks of SGLT-2 inhibitors in hospitalized patients, and who might be good candidates for safer alternatives like DPP-4 inhibitors and insulin. Packed with valuable insights and practical strategies, this discussion is essential for optimizing hospital-based diabetes care. Read the full article in the April 2024 issue of EP here.

There are no comments yet.

Please log in to write the first comment.